5 Ways Cardiac Insight is Expanding Access to AFib Diagnosis and Treatment

5 Ways Cardiac Insight is Expanding Access to AFib Diagnosis and Treatment

To find the right solution, you must first know a problem exists. During AFib (Atrial Fibrillation) Awareness Month this September, cardiologists, electrophysiologists, clinicians, and the wider cardiology community including Cardiac Insight are raising awareness and a collective voice to ensure the public understands the magnitude and seriousness of AFib.

AFib is the occurrence of a quivering or irregular heartbeat (arrhythmia) that often leads to blood clots, stroke, heart failure and even death. The toll it takes on patients, their loved ones, and the healthcare system is extreme. AFib alone increases a person’s risk of stroke by 500 percent, yet most people are not even aware that it is a serious condition (Source: AHA). Far too often, it’s left undetected and untreated.

During AFib Awareness Month and throughout the year, Cardiac Insight is working hard to increase patient and clinician access to effective AFib diagnosis and treatment.

The first step in finding the right solution for AFib is detection. Cardiac Insight’s Cardea SOLO™ ECG test kit and analysis software provides efficient, patient-friendly, ambulatory monitoring to ensure even those far from a cardiologist office can still utilize the latest technology to track and diagnose AFib.

The 5 Ways Cardiac Insight Expands Access

1. Providing Telehealth Solutions – As COVID-19 continues to be a major health concern, patients can still work with their medical providers for diagnosis of cardiac health conditions without leaving their homes. With a prescription, Cardiac Insight will ship the Cardea SOLO ECG test kit with complete, simple-to-follow instructions directly to a patient without the worry or lost time of scheduling an office visit. After the optimal, prescribed wear time (typically seven days), the patient simply mails the SOLO Sensor to the clinician using the included, pre-addressed envelope. Even beyond COVID-19, patients in rural communities without close access to a clinic will be able to access critical, prompt AFib diagnoses with Cardea SOLO.

2. Enabling Cardiac Diagnosis at your Primary Care Provider – Concerns about AFib symptoms such as general fatigue, rapid and irregular heartbeat, dizziness, shortness of breath, fatigue or fainting, can be addressed at a patient’s primary care provider who can access the Cardea SOLO diagnostic technology with the same ease as a cardiology practice. The device has already obtained FDA 510(k) clearance with favorable insurance reimbursements.

3. Increasing Clinician Bandwidth with Optimal Turnaround Time – After patients wear the comfortable, discreet Cardea SOLO Sensor patch for the optimal period of seven days, the recorded ECG data is then analyzed in-clinic. Within moments of receiving the Sensor, clinicians can download the complete ECG data set and, using Cardiac Insight’s proven, automated, algorithm-based software, generate a draft summary report for clinician review. Instead of costly outsourcing of data analysis, which typically takes weeks, the time to diagnosis is much faster, allowing patients to access critical treatment more quickly and giving doctors more bandwidth to treat more patients.

4. Providing Clinicians with the “Big Picture” – Cardea SOLO empowers doctors with 100% of the patient’s ECG data before and after a patient-identified symptom marker. Clinicians have the option to add or remove ECG strips from the report and can view any heartbeat from any time the Sensor was worn. With traditional service centers for outsourced data analysis, clinicians would have to wait weeks­­­, or never even have access to this data.

5. Building a Bridge to the Cardiac Care of the Future – Cardiac Insight is a leading technology choice for renowned researchers who are charting the next frontier for cardiac health. Our products, including the Cardea SOLO, are used by major academic and industry researchers in the US and around the world including Fortune 100 companies and eminent research universities.

AFib Awareness Month is commemorated every September. Learn more about the foundation and future for Cardea SOLO in this blog post.